NFL BIOSCIENCES announces that its 2021 annual accounts, prepared in accordance with French accounting standards, were approved by the Board of Directors at its meeting on March 24, 2022. The audit procedures on the annual accounts have been finalized. The Statutory Auditors’ Reports will be issued after finalization of the Management Report, prior to the publication of the Annual Financial Report.
The listing on Euronext Growth Paris in July 2022 resulted in the recording of an issue premium of 4,960,724.34 euros, and shareholders’ equity was increased to 3,287,481 euros. The gross amount received is 5 ME.
The operating result, at (978 K), reflects the costs incurred to implement the CESTO II clinical study, with in particular the reinforcement of the teams from the 3rd quarter of 2022, the manufacture of batches of active ingredients, and the payments to CROs.
In order to optimize these resources, NFL Biosciences mobilizes various financing mechanisms which are reflected in the debt of 270.7 KE and the research tax credit for 141.8 KE. Various requests for additional public funding are in progress, in France and abroad.
Perspectives 2022
Dr. Ignacio Faus, Chief Executive Officer of NFL Biosciences, said, “NFL Biosciences continues to implement the Phase II/III clinical trial for NFL-101 (smoking cessation), as well as the development of NFL-201 (cannabis addiction) and NFL-301 (reduction of alcohol consumption).In line with our international development strategy, the company will intensify initiatives allowing the development of NFL-101 and NFL-301 in the United States. Within this framework, meetings are scheduled with the US FDA, with the main objective of ensuring that the development plan for drug candidates and future clinical trials are acceptable to the FDA.
During the Covid-19 pandemic, tobacco and alcohol consumption increased dramatically in most countries. More than ever, there is a need for safe, effective and natural medicines that will have a lasting impact in the lives of millions of people who want to quit smoking and reduce their alcohol consumption.”
